Torren Management’s Intellia Therapeutics NTLA Stock Holding History

Torren Management’s Portfolio NTLA Stock Details NTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-99	Closed	-$890	–	1285
2025 Q4	$890	Buy	+99	New	+$1.36K	﹤0.01%	1218

Other funds holding NTLA

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Torren Management's NTLA Position: Q1 2026 in Review

Torren Management sold out of Intellia Therapeutics (NTLA) in Q1 2026, closing a stake of 99 shares — an estimated $890 sold.

Torren Management first reported a position in NTLA in Q4 2025 and held it in 1 quarter. The position peaked at $890 in Q4 2025. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

Torren Management reported no remaining Intellia Therapeutics position as of Q1 2026 after selling out during the quarter.
Torren Management sold 99 Intellia Therapeutics shares in Q1 2026, an estimated $890.
Torren Management first reported a position in Intellia Therapeutics in Q4 2025 and held it in 1 quarter.
Torren Management's Intellia Therapeutics position peaked at $890 in Q4 2025.
303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Torren Management's 13F filing for Q1 2026, filed 30 Apr 2026.